FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney DiseaseGlobeNewsWire • 02/11/20
Are Options Traders Betting on a Big Move in FibroGen (FGEN) Stock?Zacks Investment Research • 12/24/19
FibroGen Submits New Drug Application to the U.S. FDA for Roxadustat in Patients With Anemia of Chronic Kidney DiseaseGlobeNewsWire • 12/23/19
FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug ListGlobeNewsWire • 12/02/19
FibroGen, Inc. (FGEN) CEO James Schoeneck on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/13/19
FibroGen Overcomes Safety Hurdle; Clear Path Towards FDA Approval For CKD PatientsSeeking Alpha • 11/12/19
FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney DiseaseGlobeNewsWire • 11/08/19
FibroGen Announces First Patient Dosed in LAPIS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients With Locally Advanced Pancreatic Cancer GlobeNewsWire • 10/23/19
Roxadustat Global Phase 3 Results for Treatment of Chronic Kidney Disease (CKD) Anemia to be Presented at American Society of Nephrology Kidney Week 2019GlobeNewsWire • 10/11/19
FibroGen Receives One of China Pharmaceutical Industry’s Highest Awards for Clinical Innovation for RoxadustatGlobeNewsWire • 10/01/19
FibroGen Announces Publication in the Lancet Respiratory Medicine of Positive Pamrevlumab Efficacy and Safety Data for the Praise Phase 2 Study in Idiopathic Pulmonary FibrosisGlobeNewsWire • 09/30/19
FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving ChemotherapyGlobeNewsWire • 09/26/19